Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
By Sandra V. Navarra, R. Guzman, A. Gallacher, S. Hall, Roger A Levy, R. Jimenez, Edmund K. Li, Mathew Thomas, Ho‐Youn Kim, M. G. Leon and 7 more. The Lancet, 2011
1,775 citations recorded by the source corpus.
Subfields: Neurology, Pathology and Forensic Medicine, Rheumatology
View Paper: https://www.semanticscholar.org/paper/7337c177faa02bb09ddc864db33c3953a54f5b12
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Rheumatology
Citations in the corpus
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus (2019, positive): “66 Belimumab should be considered in extrarenal disease with inadequate control (ongoing disease activity or frequent flares) to first-line treatments (typically including combination of HCQ and prednisone with or without IS agents), and inability to taper GC daily dose to acceptable levels (ie,…”
- Personalized Immunomonitoring Uncovers Molecular Networks That Stratify Lupus Patients (2016, neutral): “Conversely, they displayed lower responses to anti-BAFF treatment in a phase III clinical trial (Navarra et al., 2011).”
- American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis (2012, background): “Patients with active SLE (Systemic Lupus Erythematosus Disease Activity Index score 6, excluded if there was severe active nephritis) received IV belimumab or placebo in addition to glucocorticoids and an immunosuppressive agent (70,71).”